학술논문
Somatostatin Receptor Imaging with [ 18 F]FET-βAG-TOCA PET/CT and [ 68 Ga]Ga-DOTA-Peptide PET/CT in Patients with Neuroendocrine Tumors: A Prospective, Phase 2 Comparative Study.
Document Type
Academic Journal
Author
Dubash S; Department of Surgery and Cancer, Imperial College London, London, United Kingdom.; Barwick TD; Department of Surgery and Cancer, Imperial College London, London, United Kingdom.; Department of Imaging, Imperial College Healthcare NHS Trust, London, United Kingdom.; Kozlowski K; Department of Surgery and Cancer, Imperial College London, London, United Kingdom.; Rockall AG; Department of Surgery and Cancer, Imperial College London, London, United Kingdom.; Khan S; Department of Imaging, Imperial College Healthcare NHS Trust, London, United Kingdom.; Khan S; Department of Imaging, Imperial College Healthcare NHS Trust, London, United Kingdom.; Yusuf S; Radiology and Nuclear Medicine Department, Royal Marsden NHS Foundation Trust, London, United Kingdom.; Lamarca A; Division of Cancer Sciences, University of Manchester, Manchester, United Kingdom.; Department of Medical Oncology, The Christie NHS Foundation Trust, Manchester, United Kingdom.; Valle JW; Division of Cancer Sciences, University of Manchester, Manchester, United Kingdom.; Department of Medical Oncology, The Christie NHS Foundation Trust, Manchester, United Kingdom.; Hubner RA; Division of Cancer Sciences, University of Manchester, Manchester, United Kingdom.; Department of Medical Oncology, The Christie NHS Foundation Trust, Manchester, United Kingdom.; McNamara MG; Division of Cancer Sciences, University of Manchester, Manchester, United Kingdom.; Department of Medical Oncology, The Christie NHS Foundation Trust, Manchester, United Kingdom.; Frilling A; Department of Surgery and Cancer, Imperial College London, London, United Kingdom.; Tan T; Department of Endocrinology, Imperial College Healthcare NHS Trust, London, United Kingdom.; Wernig F; Department of Endocrinology, Imperial College Healthcare NHS Trust, London, United Kingdom.; Todd J; Department of Endocrinology, Imperial College Healthcare NHS Trust, London, United Kingdom.; Meeran K; Department of Endocrinology, Imperial College Healthcare NHS Trust, London, United Kingdom.; Pratap B; Department of Surgery and Cancer, Imperial College London, London, United Kingdom.; Azeem S; Invicro-London, Imperial College London, London, United Kingdom; and.; Huiban M; Invicro-London, Imperial College London, London, United Kingdom; and.; Keat N; Invicro-London, Imperial College London, London, United Kingdom; and.; Lozano-Kuehne JP; Department of Surgery and Cancer, Imperial College London, London, United Kingdom.; Population Health Sciences Institute, Faculty of Medical Sciences, University of Newcastle, Newcastle, United Kingdom.; Aboagye EO; Department of Surgery and Cancer, Imperial College London, London, United Kingdom.; Sharma R; Department of Surgery and Cancer, Imperial College London, London, United Kingdom; r.sharma@imperial.ac.uk.
Source
Publisher: Society of Nuclear Medicine Country of Publication: United States NLM ID: 0217410 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1535-5667 (Electronic) Linking ISSN: 01615505 NLM ISO Abbreviation: J Nucl Med Subsets: MEDLINE
Subject
Language
English
Abstract
There is a clinical need for 18 F-labeled somatostatin analogs for the imaging of neuroendocrine tumors (NET), given the limitations of using [ 68 Ga]Ga-DOTA-peptides, particularly with regard to widespread accessibility. We have shown that [ 18 F]fluoroethyl-triazole-[Tyr 3 ]-octreotate ([ 18 F]FET-βAG-TOCA) has favorable dosimetry and biodistribution. As a step toward clinical implementation, we conducted a prospective, noninferiority study of [ 18 F]FET-βAG-TOCA PET/CT compared with [ 68 Ga]Ga-DOTA- peptide PET/CT in patients with NET. Methods: Forty-five patients with histologically confirmed NET, grades 1 and 2, underwent PET/CT imaging with both [ 18 F]FET-βAG-TOCA and [ 68 Ga]Ga-peptide performed within a 6-mo window (median, 77 d; range, 6-180 d). Whole-body PET/CT was conducted 50 min after injection of 165 MBq of [ 18 F]FET-βAG-TOCA. Tracer uptake was evaluated by comparing SUV max and tumor-to-background ratios at both lesion and regional levels by 2 unblinded, experienced readers. A randomized, blinded reading of both scans was also then undertaken by 3 experienced readers, and consensus was assessed at a regional level. The ability of both tracers to visualize liver metastases was also assessed. Results: A total of 285 lesions were detected on both imaging modalities. An additional 13 tumor deposits were seen in 8 patients on [ 18 F]FET-βAG-TOCA PET/CT, and [ 68 Ga]Ga-DOTA-peptide PET/CT detected an additional 7 lesions in 5 patients. Excellent correlation in SUV max was observed between both tracers ( r = 0.91; P < 0.001). No difference was observed between median SUV max across regions, except in the liver, where the median tumor-to-background ratio of [ 18 F]FET-βAG-TOCA was significantly lower than that of [ 68 Ga]Ga-DOTA-peptide (2.5 ± 1.9 vs. 3.5 ± 2.3; P < 0.001). Conclusion: [ 18 F]FET-βAG-TOCA was not inferior to [ 68 Ga]Ga-DOTA-peptide in visualizing NET and may be considered in routine clinical practice given the longer half-life and availability of the cyclotron-produced fluorine radioisotope.
(© 2024 by the Society of Nuclear Medicine and Molecular Imaging.)
(© 2024 by the Society of Nuclear Medicine and Molecular Imaging.)